Groundbreaking discovery offers hope for patients suffering from toxic epidermal necrolysis

A global team of researchers at the Max Planck Institute of Biochemistry has made a groundbreaking discovery that saves the lives of patients suffering from toxic epidermal necrolysis.

FDA approves Madrigal’s Rezdiffra as the first NASH therapy – Pharmaceutical Technology

Share this article According to GlobalData analysis, Rezdiffra is expected to generate $1bn in global sales in 2027. Image Credit: BlurryMe / Shutterstock. Madrigal Pharmaceuticals’

March 15, 2024

Oversight of health AI must be democratic, not done by the big tech companies

AI development is at a flash point; developers from some of the largest, most successful companies in the world are leaving high-paying jobs to start

June 17, 2024

Clade Therapeutics cuts staff and appears to shut down European subsidiary

Clade Therapeutics, which is developing off-the-shelf cell therapies, has dismissed a number of staffers in the US and Europe, according to social media posts made

February 24, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.